Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.

[1]  D. Gillatt,et al.  BCG immunotherapy for superficial bladder cancer , 2001, Journal of the Royal Society of Medicine.

[2]  E. Ernst.  A primer of complementary and alternative medicine commonly used by cancer patients , 2001, The Medical journal of Australia.

[3]  R. Greenberg,et al.  Maintenance therapy for superficial bladder cancer. , 2001, Oncology.

[4]  S. Nilsson,et al.  A systematic overview of chemotherapy effects in urothelial bladder cancer. , 2001, Acta oncologica.

[5]  T. Lenarz,et al.  The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. , 2001, European journal of cancer.

[6]  B. Kupelnick,et al.  Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. , 2001, Anticancer research.

[7]  J. Pow-Sang,et al.  Contemporary management of superficial bladder cancer. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[8]  D. Lenartz,et al.  Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. , 2000, Anticancer research.

[9]  J. Beuth,et al.  Lebensqualitätsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalen Karzinom , 1998, Der Onkologe.

[10]  J. Beuth,et al.  Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. , 1998, Anticancer research.

[11]  P. Berg,et al.  Mistletoe extract-induced effects on immunocompetent cells: in vitro studies , 1997, Anti-cancer drugs.

[12]  P. Poindron,et al.  Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. , 1996, Cancer letters.

[13]  Luc Bijnens,et al.  A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer , 1996 .

[14]  D. Lenartz,et al.  Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. , 1996, Anticancer research.

[15]  S. Krege,et al.  A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. , 1996, The Journal of urology.

[16]  R Sylvester,et al.  Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. E , 1995, The Journal of urology.

[17]  J. Geisel,et al.  [Comparative studies on the immunoactive action of galactoside-specific mistletoe lectin. Pure substance compared to the standardized extract]. , 1993, Arzneimittel-Forschung.

[18]  G. Uhlenbruck,et al.  DAS LEKTIN DER MISTEL IN DER ADJUVANTEN THERAPIE BEIM MAMMAKARZINOM : ERSTE KLINISCHE ERFAHRUNGEN , 1993 .

[19]  F M Debruyne,et al.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. , 1992, The Journal of urology.

[20]  J. Aster,et al.  Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. , 1990, The Journal of urology.

[21]  P. Scardino,et al.  Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. , 1990, The Journal of urology.

[22]  K. Frei,et al.  Increased Secretion of Tumor Necrosis Factor α, Interleukin 1, and Interleukin 6 by Human Mononuclear Cells Exposed to β-Galactoside-specific Lectin from Clinically Applied Mistletoe Extract , 1990 .

[23]  H. Gabius,et al.  Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. , 1989, Cancer research.

[24]  H. Franz,et al.  Effects of lectin I from mistletoe (ML I) and its isolated A and B chains on human mononuclear cells: mitogenic activity and lymphokine release. , 1987, Pharmazie.

[25]  T. Hajtó,et al.  Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. , 1986, Oncology.

[26]  S. Wray,et al.  Postnatal morphological changes in rat LHRH neurons correlated with sexual maturation. , 1986, Neuroendocrinology.

[27]  S. Brosman.  Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma. , 1982, The Journal of urology.